Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study

Area of Science:

• Cardiology
• Pharmacology

Background:

• Conventional antiarrhythmic drugs pose proarrhythmic risks.
• Cardiac nicotinic acetylcholine receptors (nAChRs) offer a novel therapeutic target.

Purpose of the Study:

• To evaluate varenicline's efficacy and safety in reducing premature ventricular complexes (PVCs) post-myocardial infarction (MI).
• To assess varenicline's biological target engagement and antiarrhythmic potential.

Main Methods:

• A multicenter, randomized, double-blind, placebo-controlled phase 2 trial.
• 118 adults with frequent PVCs post-MI received varenicline or placebo for 45 days.
• Primary endpoint: percentage change in 24-hour PVC count; secondary endpoints: responder rate and nonsustained ventricular tachycardia (VT) incidence.

Main Results:

• Varenicline significantly reduced PVC burden by 60.1% compared to placebo (P = 0.001).
• Higher responder rates (67.8% vs 30.5%) and lower nonsustained VT incidence (20.3% vs 37.3%) were observed with varenicline.
• Adverse event rates were comparable, with no deaths or malignant ventricular arrhythmias in the varenicline group.

Conclusions:

• Varenicline effectively reduces PVC burden and VT incidence in post-MI patients without proarrhythmic effects.
• Cardiac nAChRs are a viable antiarrhythmic target.
• Further large-scale outcome trials are warranted to confirm these findings.